Bausch + Lomb (BLCO) return on equity (ROE)

Return on equity · fiscal 2025
-5.6%

Bausch + Lomb (BLCO) earned a return on equity of -5.6% in fiscal 2025 (the year ended December 31, 2025). That is 0.7 percentage points lower than the -4.9% of fiscal 2024. Figures as of 17 Nov 2026, 23:42 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-5.6%
Change on fiscal 2024
−0.7 pts
Highest on record
2.0%fiscal 2021
Lowest on record
-5.6%fiscal 2025
Fiscal years on record
62020–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Bausch + Lomb return on equity (ROE), in more detail

Across the 6 fiscal years on record (2020–2025), the highest was 2.0% in fiscal 2021 and the lowest -5.6% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 5 earlier fiscal years on record, whose median is -0.2%.

History · 6 fiscal years

Return on equity by fiscal year

Bausch + Lomb return on equity (ROE), year by year

Bausch + Lomb (BLCO) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-5.6% 0.7 pts down
2024-4.9% 1.1 pts down
2023-3.8% 3.9 pts down
20220.1% 1.9 pts down
20212.0% 2.1 pts up
2020-0.2%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Bausch + Lomb and comparable companies
CompanyReturn on equityFiscal year
ImmunityBio IBRX-130.7%2019
Cytokinetics CYTK-88.3%2021
ABIVAX ABVX-73.8%2025
Bausch + Lomb BLCO-5.6%2025
Amneal Pharmaceuticals AMRX-424.6%2023
Caris Life Sciences CAI-11.8%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BLCO

Bausch + Lomb, figure by figure

Bausch + Lomb (BLCO) overview: price, valuation and scorecardAll health care companies by market value

Bausch + Lomb return on equity (ROE): questions and answers

What is Bausch + Lomb's return on equity?

Bausch + Lomb (BLCO) earned a return on equity of -5.6% in fiscal 2025 (the year ended December 31, 2025). That is 0.7 percentage points lower than the -4.9% of fiscal 2024.

Is Bausch + Lomb's return on equity high or low compared with its own history?

The fiscal 2025 figure is no higher than in any of the 5 earlier fiscal years on record, whose median is -0.2%.

What are the highest and lowest return on equity figures on record for Bausch + Lomb?

Across the 6 fiscal years on record (2020–2025), the highest was 2.0% in fiscal 2021 and the lowest -5.6% in fiscal 2025.

How is Bausch + Lomb's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Bausch + Lomb (BLCO) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/BLCO/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.